# US 2026/0028385 A1 · Compositions and methods for the treatment of metabolic and liver disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0028385 A1
- Document ID: US20260028385A1
- Status: Published application
- Kind: A1
- Application number: 18/995,504
- Filed: 2023-07-18
- Published: 2026-01-29
- Earliest claimed: 2022-07-20
- Applicants: Viking Therapeutics, Inc.
- Inventors: Brian Lian; Geoffrey E. Barker; Erland Stevens; Brahmachary Enugurthi
- Web page: https://patentgrep.com/patent/US20260028385A1

## CPC

- C07K 14/605: Glucagons
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/02: Suppositories; Bougies; Bases therefor; {Ovules}(apparatus for making A61J3/08; devices for introducing into the body A61M31/00)
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/4858: {Organic compounds}
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/548: {Phosphates or phosphonates, e.g. bone-seeking (phospholipids A61K47/544)}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/10: Dispersions; Emulsions
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are small molecule GLP-1 receptor agonist compounds, pharmaceutical compositions, and the use and preparation thereof.

## Claims

### Claim 1

A compound having the structure of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from the group consisting of —C(═O)(OZ1), —P(═O)(X)(Y) and a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O and S optionally substituted with 1-2 R7 independently selected from halogen, C1-6 alkyl, haloC1-6 alkyl, haloC1-6 alkoxy, —OR5, C3-10 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl and 5-10 membered heterocyclyl;
R2 is selected from the group consisting of —C(═O)(OZ2), —(CH2CH2)nP(═O)(X)(Y) and a 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O and S optionally substituted with 1-2 R7 independently selected from halogen, C1-6 alkyl, haloC1-6 alkyl, haloC1-6 alkoxy, —OR5, C3-10 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl and 5-10 membered heterocyclyl;
each R7 is independently selected from the group consisting of halogen, C1-6 alkyl, haloC1-6 alkyl, haloC1-6 alkoxy, C1-6 alkoxy, C3-10 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl and 5-10 membered heterocyclyl;
X and Y each are independently selected from the group consisting of —OR4, NR5R6, C1-6 alkyl and haloC1-6 alkyl;
each R4 is independently selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, C6-10 aryloxy and C6-10 aryl alkoxy;
each R5 is independently hydrogen or C1-6 alkyl;
each R6 is independently hydrogen or C1-6 alkyl;
Z1 and Z2 each are independently selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, haloC1-6 alkoxy, C1-6 alkoxy, C3-10 cycloalkyl and C6-10 aryl; and
n is 0, 1, 2, 3 or 4,
wherein at least one of Z1 and Z2 is not hydrogen.

### Claim 2 (depends on 1)

The compound of claim 1, having the structure of Formula (I-a):
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The compound of claim 2, wherein Z1 is selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, haloC1-6 alkoxy, C1-6 alkoxy, C3-10 cycloalkyl and C6-10 aryl; and X and Y each are —OR4.

### Claim 4 (depends on 2, 3)

The compound of claim 2 or 3, wherein Z1 is selected from the group consisting of hydrogen, haloC1-6 alkoxy and C1-6 alkoxy; and each R4 independently is selected from the group consisting of hydrogen, C6-10 aryloxy and C6-10 aryl alkoxy.

### Claim 5 (depends on 2, 3, 4)

The compound of any one of claims 2 to 4, wherein Z1 is hydrogen and each R4 independently is hydrogen or C6-10 aryl alkoxy.

### Claim 6 (depends on 2, 3, 4, 5)

The compound of any one of claims 2 to 5, wherein each R4 is hydrogen.

### Claim 7 (depends on 2, 3, 4, 5, 6)

The compound of any one of claims 2 to 6, wherein Z1 is hydrogen and each R4 is hydrogen.

### Claim 8 (depends on 2, 3, 4, 5, 6, 7)

The compound of any one of claims 2 to 7, wherein n is 1.

### Claim 9 (depends on 2, 3, 4, 5, 6, 7)

The compound of any one of claims 2 to 7, wherein n is 2.

### Claim 10 (depends on 1)

The compound of claim 1, having the structure of Formula (I-b):
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 10)

The compound of claim 10, wherein Z2 is selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, haloC1-6 alkoxy, C1-6 alkoxy, C3-10 cycloalkyl and C6-10 aryl; and X and Y each are —OR4.

### Claim 12 (depends on 10, 11)

The compound of claim 10 or 11, wherein Z2 is selected from the group consisting of hydrogen, haloC1-6 alkoxy and C1-6 alkoxy; and each R4 independently is selected from the group consisting of hydrogen, C6-10 aryloxy and C6-10 aryl alkoxy.

### Claim 13 (depends on 10, 11, 12)

The compound of any one of claims 10 to 12, wherein Z2 is hydrogen and each R4 is hydrogen or C6-10 aryl alkoxy.

### Claim 14 (depends on 10, 11, 12, 13)

The compound of any one of claims 10 to 13, wherein each R4 is hydrogen.

### Claim 15 (depends on 10, 11, 12, 13)

The compound of any one of claims 10 to 13, wherein Z2 is hydrogen and each R4 is hydrogen.

### Claim 16 (depends on 10, 11, 12, 13, 14, 15)

The compound of any one of claims 10 to 15, wherein n is 1.

### Claim 17 (depends on 10, 11, 12, 13, 14, 15)

The compound of any one of claims 10 to 15, wherein n is 2.

### Claim 18 (depends on 1)

The compound of claim 1, having the structure of Formula (I-c):
or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 18)

The compound of claim 18, wherein X and Y each are —OR4.

### Claim 20 (depends on 19)

The compound of claim 19, wherein each R4 independently is selected from the group consisting of hydrogen, C6-10 aryloxy and C6-10 aryl alkoxy.

### Claim 21 (depends on 19, 20)

The compound of claim 19 or 20, wherein each R4 is hydrogen.

### Claim 22 (depends on 18, 19, 20, 21)

The compound of any one of claims 18 to 21, wherein n is 1.

### Claim 23 (depends on 18, 19, 20, 21)

The compound of any one of claims 18 to 21, wherein n is 2.

### Claim 24 (depends on 1)

The compound of claim 1, having the structure selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The compound of any one of claims 1 to 24, wherein “*” indicates a chiral carbon with “S” configuration.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The compound of any one of claims 1 to 24, wherein “*” indicates a chiral carbon with “R” configuration.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1 to 26 and a pharmaceutically acceptable excipient.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A method of preventing, treating, or ameliorating one or more fatty liver diseases in a subject, comprising administering a compound of any one of claims 1 to 26, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

### Claim 29 (depends on 28)

The method of claim 28, wherein said wherein said fatty liver disease is selected from the group consisting of steatosis, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.

### Claim 30 (depends on 28, 29)

The method of claim 28 or 29, wherein said administration of said compound results in the prevention, treatment, or amelioration, of a fibrosis, fibrotic condition, or fibrotic symptoms.

### Claim 31 (depends on 28, 29, 30)

The method of any one of claims 28 to 30, wherein said administration of said compound results in the reduction in the amount of extracellular matrix proteins present in one or more tissues of said subject.

### Claim 32 (depends on 28, 29, 30, 31)

The method of any of claims 28 to 31, wherein said administration of said compound results in the reduction in the amount of collagen present in one or more tissues of said subject.

### Claim 33 (depends on 32)

The method of claim 32, wherein said administration of said compound results in the reduction in the amount of Type I, Type Ia, or Type III collagen present in one or more tissues of said subject.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A method of preventing, treating, or ameliorating one or disease or disorders in a subject, comprising administering a compound of any one of claims 1 to 26, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein said disease or disorder is a metabolic disorder, liver fibrosis, renal fibrosis, biliary fibrosis, pancreatic fibrosis, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis, primary biliary cirrhosis, or idiopathic fibrosis.

### Claim 35 (depends on 34)

The method of claim 34, wherein said disease or disorder is nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis, or primary biliary cirrhosis.

### Claim 36 (depends on 34)

The method of claim 34, wherein said disease or disorder is atherosclerosis, diabetes, hyperglycemic diabetes, type 2 diabetes mellitus, dyslipidemia, hypercholesterolemia, hyperlipidemia, hypertension, hypoglycemia, obesity, or prader-willi syndrome.

### Claim 37 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 28 to 36, wherein the compound activates a glucagon-like peptide-1 (GLP-1) receptor.

### Claim 38 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 28 to 37, wherein the subject is a mammal.

### Claim 39 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 28 to 38, wherein the subject is a human.

### Claim 40 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 28 to 39, wherein the route of administration is selected from the group consisting of: enteral, intravenous, oral, intraarticular, intramuscular, subcutaneous, intraperitoneal, epidural, transdermal, and transmucosal.
